Evidence map›Paper›PMID 37398339›Full record

ArticlebioRxiv : the preprint server for biology2024

Structural characterization of ligand binding and pH-specific enzymatic activity of mouse Acidic Mammalian Chitinase.

Roberto Efraín Díaz, Andrew K Ecker, Galen J Correy, Pooja Asthana, Iris D Young, Bryan Faust, Michael C Thompson, Ian B Seiple, Steven J Van Dyken, Richard M Locksley and 1 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Roberto Efraín DíazDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0002-1172-9919
Andrew K EckerDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0001-7331-0825
Galen J CorreyDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0001-5155-7325
Pooja AsthanaDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0002-3417-9198
Iris D YoungDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0003-4713-9504
Bryan FaustDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0002-4126-6409
Michael C ThompsonDepartment of Chemistry and Chemical Biology, University of California, Merced, Merced, CA 95343, USA.ORCID 0000-0002-6099-2027
Ian B SeipleDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0002-8732-1362
Steven J Van DykenDepartment of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, MO 63110, USA.ORCID 0000-0002-9787-0883
Richard M LocksleyDepartment of Medicine, University of California, San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0002-5468-6867
James S FraserDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0002-5080-2859
University of California, San Francisco · USHoward Hughes Medical Institute · USUniversity of California, Merced · USWashington University in St. Louis · US

Funding

X-ray Absorption Spectroscopy (XAS) pp.711-759P41GM103393 · NIGMS · STANFORD UNIVERSITY · PI HODGSON, KEITH O · 2012 to 2019
$30.6M
User Training and OutreachP30GM124169 · NIGMS · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI Jay C. Nix · 2017 to 2026
$28.6M
Eliminating Critical Systematic Errors In Structural Biology With Next-Generation SimulationR01GM124149 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HOLTON, JAMES M · 2017 to 2024
$2.5M
Targeting chitin in fibrotic lung diseaseR01HL148033 · NHLBI · WASHINGTON UNIVERSITY · PI VAN DYKEN, STEVEN · 2020 to 2023
$1.7M
Prevention and Public Health FundH23IP000554 · IP · CONNECTICUT STATE DEPT OF PUBLIC HEALTH · PI SACCO, VINCENT A · 2011 to 2011
$1.6M
NCIRD CDC HHS H23 IP000554NHLBI NIH HHS R01 HL148033NIGMS NIH HHS P30 GM124169NIGMS NIH HHS P41 GM103393NIGMS NIH HHS R01 GM124149
6 · The paper itself

Abstract

Chitin is an abundant biopolymer and pathogen-associated molecular pattern that stimulates a host innate immune response. Mammals express chitin-binding and chitin-degrading proteins to remove chitin from the body. One of these proteins, Acidic Mammalian Chitinase (AMCase), is an enzyme known for its ability to function under acidic conditions in the stomach but is also active in tissues with more neutral pHs, such as the lung. Here, we used a combination of biochemical, structural, and computational modeling approaches to examine how the mouse homolog (mAMCase) can act in both acidic and neutral environments. We measured kinetic properties of mAMCase activity across a broad pH range, quantifying its unusual dual activity optima at pH 2 and 7. We also solved high resolution crystal structures of mAMCase in complex with oligomeric GlcNAcn, the building block of chitin, where we identified extensive conformational ligand heterogeneity. Leveraging these data, we conducted molecular dynamics simulations that suggest how a key catalytic residue could be protonated via distinct mechanisms in each of the two environmental pH ranges. These results integrate structural, biochemical, and computational approaches to deliver a more complete understanding of the catalytic mechanism governing mAMCase activity at different pH. Engineering proteins with tunable pH optima may provide new opportunities to develop improved enzyme variants, including AMCase, for therapeutic purposes in chitin degradation.

Identifiers

PMID37398339
PMCPMC10312649
OpenAlexW4379284907

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.